论文部分内容阅读
目的:比较甘精胰岛素和持续皮下输注胰岛素(CSII)治疗围手术期2型糖尿病患者的疗效和安全性。方法:59例拟手术治疗的2型糖尿病患者分为甘精胰岛素组(29例)和胰岛素泵CSII组(30例),观察其血糖控制水平、达标时间、低血糖次数、切口感染和延迟愈合等指标。结果:两组患者均能获得良好的血糖控制,甘精胰岛素组血糖达标时间、术中和术后血糖、低血糖次数、延迟愈合例数均与CSII组无显著差异。结论:甘精胰岛素治疗可以达到和CSII治疗同样的效果,有效、迅速、平稳地控制2型糖尿病患者围手术期的高血糖,缩短术前准备时间,减少低血糖、伤口感染以及延迟愈合等并发症的发生。
Objective: To compare the efficacy and safety of insulin glargine and continuous subcutaneous infusion of insulin (CSII) in the treatment of perioperative type 2 diabetes mellitus. Methods: Fifty-nine patients with type 2 diabetes mellitus undergoing surgical treatment were randomly divided into insulin glargine group (n = 29) and insulin pump group CSII (n = 30). The levels of glycemic control, time to target, number of hypoglycemia, incision infection and delayed union And other indicators. Results: Good glycemic control was obtained in both groups. There was no significant difference in the glycemic index, blood glucose, the number of hypoglycemic episodes and the number of delayed healing between glargine group and CSII group. Conclusion: Glargine treatment can achieve the same effect as CSII treatment, effectively, rapidly and smoothly control perioperative hyperglycemia, shorten preoperative preparation time, reduce hypoglycemia, wound infection and delayed healing in patients with type 2 diabetes mellitus Occurrence of the disease.